These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3408808)

  • 1. Synergism between zymosan-activated serum and heparin in the induction of polymorphonuclear leukocyte aggregation.
    Berliner S; Fishelson Z; Wasserman L; Pinkhas J; Aronson M
    Biomed Pharmacother; 1988; 42(1):69-72. PubMed ID: 3408808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of anti-C5a antibodies on human polymorphonuclear leukocyte function: chemotaxis, chemiluminescence, and lysosomal enzyme release.
    Hatherill JR; Stephens KE; Nagao K; Ishizaka A; Wilmarth L; Wang JC; Deinhart T; Larrick JW; Raffin TA
    J Biol Response Mod; 1989 Dec; 8(6):614-24. PubMed ID: 2600603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia.
    Craddock PR; Hammerschmidt D; White JG; Dalmosso AP; Jacob HS
    J Clin Invest; 1977 Jul; 60(1):260-4. PubMed ID: 874088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of granulocytes and C5a in myocardial response to zymosan-activated serum.
    Stahl GL; Fletcher MP; Amsterdam EA; Longhurst JC
    Am J Physiol; 1991 Jul; 261(1 Pt 2):H29-37. PubMed ID: 1677537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus.
    Perez HD; Lipton M; Goldstein IM
    J Clin Invest; 1978 Jul; 62(1):29-38. PubMed ID: 659635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of C5a/C5a(desArg) in bovine plasma, serum and milk.
    Rainard P; Sarradin P; Paape MJ; Poutrel B
    Vet Res; 1998; 29(1):73-88. PubMed ID: 9559522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The release of C5a in complement-activated serum does not require C6.
    Biesecker G; Wagner JL; Hugli TE
    J Immunol; 1989 Aug; 143(4):1228-32. PubMed ID: 2545783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effect of heparin and related glycosaminoglycans on neutrophil chemotaxis.
    Matzner Y; Marx G; Drexler R; Eldor A
    Thromb Haemost; 1984 Oct; 52(2):134-7. PubMed ID: 6084320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular reactivity of polymorphonuclear leukocytes in psoriasis and atopic dermatitis--measurement of lucigenin-dependent chemiluminescence.
    Kapp A; Schöpf E
    Acta Derm Venereol; 1986; 66(4):285-9. PubMed ID: 2430396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotactic peptides modulate adherence of human polymorphonuclear leukocytes to monolayers of cultured endothelial cells.
    Charo IF; Yuen C; Perez HD; Goldstein IM
    J Immunol; 1986 May; 136(9):3412-9. PubMed ID: 3514759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of complement activation during cardiopulmonary bypass. Attenuation by hypothermia, heparin, and hemodilution.
    Moore FD; Warner KG; Assousa S; Valeri CR; Khuri SF
    Ann Surg; 1988 Jul; 208(1):95-103. PubMed ID: 3260474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of chemotactic factor inactivator in modulating alveolar macrophage-derived neutrophil chemotactic activity.
    Robbins RA; Justice JM; Rasmussen JK; Russ WD; Thomas KR; Rennard SI
    J Lab Clin Med; 1987 Feb; 109(2):164-70. PubMed ID: 3805869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotactic responses of human peripheral blood monocytes to the complement-derived peptides C5a and C5a des Arg.
    Marder SR; Chenoweth DE; Goldstein IM; Perez HD
    J Immunol; 1985 May; 134(5):3325-31. PubMed ID: 3884709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukocyte aggregation response to quantitative plasma levels of C3a and C5a.
    Williams JJ; Yellin SA; Slotman GJ
    Arch Surg; 1986 Mar; 121(3):305-7. PubMed ID: 3484946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
    Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of endotoxin-induced C5-derived chemotactic activity in aqueous humor.
    Rosenbaum JT; Wong K; Perez HD; Raymond W; Howes EL
    Invest Ophthalmol Vis Sci; 1984 Oct; 25(10):1184-91. PubMed ID: 6384121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphonuclear leukocyte chemotaxis in systemic lupus erythematosus.
    Perez HD; Goldstein IM
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():53-8. PubMed ID: 3612652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The in vivo effect of leukotriene B4 on polymorphonuclear leukocytes and the microcirculation. Comparison with activated complement (C5a des Arg) and enhancement by prostaglandin E2.
    Movat HZ; Rettl C; Burrowes CE; Johnston MG
    Am J Pathol; 1984 May; 115(2):233-44. PubMed ID: 6326579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation products and monocyte migratory function in trauma.
    Antrum RM; Solomkin JS
    Curr Surg; 1985; 42(4):301-3. PubMed ID: 3875452
    [No Abstract]   [Full Text] [Related]  

  • 20. Neutrophil dysfunction in sepsis. II. Evidence for the role of complement activation products in cellular deactivation.
    Solomkin JS; Jenkins MK; Nelson RD; Chenoweth D; Simmons RL
    Surgery; 1981 Aug; 90(2):319-27. PubMed ID: 7256544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.